Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment

Fig. 2

TAAs and TAA binding domain design strategy for developing multispecific CARs for solid tumors. TAAs and TSAs were selected as CAR T-cell targets. To overcome the challenges of tumor antigen off-target effects and heterogeneity, dual CARs or tandem CARs have been constructed to target dual TAAs. scFv affinity, steric hindrance, and stability were considered for the construction of CARs, and VHH nanobodies were applied as TAA binding domains to develop multispecific CARs for solid tumors

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us